Fritextsökning
Innehållstyper
-
Italian pharmaceutical company buys rights to immunotherapy from Sanofi
Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).
-
Norwegian cancer research companies merge
The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.
-
Compact and leak-tight powerhouse
Media-separated solenoid valve VYKA from Festo is virtually leak-free
-
Sobi announces agreement with Enable Injections
Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.
-
High-performance Slide Scanner for Fluorescence, Brightfield and Polarization
ZEISS Axioscan 7.
-
Efficient use of blood plasma
Blood plasma is an indispensable resource in the production of life-saving medicines. It is in high demand on global markets. To make more efficient use of this...
-
Hjärnan i 3D – efter en videostund med Matrix
Forskare i USA har skapat det största och mest detaljerade kopplingsschemat hittills av en däggdjurshjärna genom att kartlägga celler i hjärnvävnaden hos en mus...
-
FHM ska leda expertlabb för ebola och okända virussjukdomar
Folkhälsomyndigheten har fått ansvar för att driva det europeiska referenslaboratoriet för smittsamma sjukdomar som ebola, marburg och rabies. Uppdraget omfatta...
-
Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis
Free webinar organized by ZEISS.
-
ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin
More than 50 distinguished speakers from leading manufacturing companies.
-
Accelerate your Research with AI-Powered Image Analysis
Comprehensive eBook from ZEISS.
-
Scale Up Your Image Analysis
ZEISS arivis Hub for accelerated analysis and faster results.
-
Webinar: Automate your processes
Free ZEISS webinar on January 30th, 2025.
-
Takeover bid is being completed – Japanese company acquires Calliditas
Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...
-
This years Nobel prize in medicine – “Changed the understanding of how genes are controlled”
This year’s Nobel Prize in Physiology or Medicine goes to the discovery that small RNA molecules, known as microRNAs, control how genes are regulated. Understan...
-
About Microscope Ergonomics
Learn about ergonomic microscope design and how you can increase your well-being and productivity when working in clinical microscopy. Read about challenges, de...
-
Novo Nordisk to invest billions in new quality control lab
Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.
-
Quality solutions for medical device R&D applications
From R&D to the quality assurance of series production in medical device manufacturing.
-
Nytt blodtest ger hopp om diagnosmetod för ME
Ett nytt blodtest visar lovande resultat för att kunna upptäcka ME/CFS, enligt en brittisk studie. Resultaten väcker hopp om en framtida biomarkör, men metoden ...
-
ZEISS supports the transition of spatial biology to clinical research
Slide scanner ZEISS Axioscan 7 spatial biology provides scalable workflow automation.
-
SupraCube - In life Science
Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...
-
Hypothesis testing versus conspiracy theory
"How do you know what is a conspiracy theory and what is a reasonable, scientifically based conclusion?" In a column, Ingrid Lönnstedt reflects on this question.
-
Första läkemedlet mot förlossningsdepression får grönt ljus i EU
EU-kommissionen har för första gången godkänt ett läkemedel mot förlossningsdepression, närmare bestämt amerikanska Biogens Zurzuvae.
-
Vd-byte i Frost Pharma
Frost Pharma har utsett Magnus Nylén till ny vd.
BREAKING